Lilly's investigational drug retatrutide, with some patients losing 30or more of their body weight
Lilly's next-generation GLP-1 family drug retatrutide saw some patients lose 30or more of their body weight in an early clinical trial. The drug is still in development, and responses varied widely among patients. Observers said the oral drug appeared less effective than a competitor's product.
![Lilly's investigational drug retatrutide, with some patients losing 30or more of their body weight/blog-images/gen-715e2cf5-917c-45dd-b6e9-c3fcd91194e3.avif)
5In 30, Lilly released early clinical trial results for retatrutide, a next-generation GLP-1 family drug it is developing. The announcement stated that some patients lost 30or more of their body weight. The company said the results could be compared with the level of weight loss from bariatric surgery.
Clinical results varied widely from patient to patient. Some patients saw substantial weight loss, while others did not. Retatrutide is still in development, with further clinical trials and data collection under way.
Lilly's oral drug in the same class was reported to appear less effective than competitor Novo Nordisk's product. This is an important observation in comparing treatment options and market competition. The observation was assessed as significant in terms of market acceptance.
The company’s announcement focuses on the initial results available to date. It states that additional data are needed on long-term safety follow-up and the durability of the effects. The regulatory approval process and commercialization prospects have not yet been determined.
Since the clinical results were disclosed, related discussions have narrowed to comparisons of efficacy and the regulatory timeline. Additional interim clinical results and the timing of regulatory filings remain important factors in investment decisions. The timing of commercialization, pricing, and insurance coverage have not yet been determined.
Sources: The Motley Fool
Bullstory synthesized this report from the linked sources. AI may have assisted the writing process. Check the original reports for factual confirmation.